Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.5644 USD | +3.52% | -5.17% | +3.88% |
Financials (USD)
Sales 2024 * | 38.83M | Sales 2025 * | 70.15M | Capitalization | 117M |
---|---|---|---|---|---|
Net income 2024 * | -107M | Net income 2025 * | -46M | EV / Sales 2024 * | 4.07 x |
Net Debt 2024 * | 40.79M | Net Debt 2025 * | 129M | EV / Sales 2025 * | 3.51 x |
P/E ratio 2024 * |
-1.17
x | P/E ratio 2025 * |
-2.54
x | Employees | 405 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.89% |
Latest transcript on Sangamo Therapeutics, Inc.
1 day | +3.52% | ||
1 week | -5.17% | ||
1 month | +9.61% | ||
3 months | -51.34% | ||
6 months | +31.26% | ||
Current year | +3.88% |
Managers | Title | Age | Since |
---|---|---|---|
Alexander Macrae
CEO | Chief Executive Officer | 61 | 16-05-31 |
Director of Finance/CFO | 46 | 19-02-28 | |
Gregory Davis
CTO | Chief Tech/Sci/R&D Officer | - | 20-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Peg Horn
BRD | Director/Board Member | 61 | 22-12-14 |
James Meyers
BRD | Director/Board Member | 59 | 19-11-21 |
H. Parker
CHM | Chairman | 68 | 14-06-18 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
3.66% | 2 M€ | -25.75% | ||
0.49% | 14 M€ | -5.07% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 0.5644 | +3.52% | 1,329,311 |
24-05-30 | 0.5452 | -5.05% | 1,382,753 |
24-05-29 | 0.5742 | -7.58% | 1,580,697 |
24-05-28 | 0.6213 | +4.39% | 2,084,136 |
24-05-24 | 0.5952 | -3.67% | 1,477,211 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.88% | 117M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- SGMO Stock